In Celexir’s immune portfolio, Thymogen is positioned to help restore coordinated immunity in adults experiencing post-illness, post-chemotherapy, or age-related immune decline. Clinically, it’s used to regulate immune cell maturation and accelerate recovery of balanced defense, making it a practical adjunct when providers aim to re-establish healthy immunological tone without sedation or broad immunosuppression.
Mechanistically, Thymogen is a synthetic thymic dipeptide (L-Glu-L-Trp; oglufanide) originally isolated as the active fraction from the thymic complex Thymalin. It modulates T-lymphocyte differentiation and activity, tuning both adaptive and innate responses and helping normalize cytokine production and immune tolerance—core processes that drift with age.
Evidence spans preclinical and translational studies. The dipeptide has shown immunostimulatory and antitumor activity in vivo (with effects dependent on intact NK-cell function), and recent reviews of thymic bioregulators—including Thymogen—describe regulation of inflammatory pathways and proliferative activity in immune cells. That said, large, modern multicenter RCTs for aging endpoints remain limited, so clinicians should frame use as investigationalwithin immune-support programs, paired with objective markers (CBC with differential, infection frequency, inflammatory panels).
Celexir delivery & specs: ready-to-use injectable pen; typical catalog protocol 100 mcg daily for 10–14 days; >98% purity (HPLC/MS), 2–8 °C storage, and full documentation (CoA/MSDS) for compliance and repeatability in clinic workflows. Position Thymogen alongside sleep, nutrition, and stress-inflammation management to support durable immune balance.